Results 91 to 100 of about 15,205 (209)

Sacubitril/Valsartan (EntrestoTM) hospital prescribing in patients with symptomatic chronic HF with reduced ejection fraction:a UK multi-centre study [PDF]

, 2019
Background:Sacubitril/valsartan is a combination drug therapy for heart failure (HF) patients that has been shown to reduce mortality and hospitalisation.Aims:To explore clinically relevant real-life patient data regarding prescribing of sacubitril ...
Cabdi, Summaya, Dorsch, Marina, Gill, Navneet K., Jalal, Zahraa, Jones, Alan M, Khan, Nazish, Toner, Fionnuala   +6 more
core   +1 more source

Beneficial and harmful effects of sacubitril/valsartan in patients with heart failure:A systematic review of randomised clinical trials with meta-analysis and trial sequential analysis [PDF]

, 2020
Current guidelines recommend angiotensin receptor blocker neprilysin inhibitors (ARNI) (sacubitril/valsartan) as a replacement for angiotensin-converting-enzymeinhibitor (ACE-I) in heart failure with reduced ejection fraction (HFrEF) who remain ...
Bu, Fan Long, Feinberg, Joshua Buron, Hecht Olsen, Michael, Jakobsen, Janus Christian, Nielsen, Emil Eik, Raymond, Ilan, Steensgaard-Hansen, Frank   +6 more
core   +1 more source

Contemporary characteristics and outcomes in chagasic heart failure compared with other nonischemic and ischemic cardiomyopathy [PDF]

, 2017
Background: Chagas’ disease is an important cause of cardiomyopathy in Latin America. We aimed to compare clinical characteristics and outcomes in patients with heart failure (HF) with reduced ejection fraction caused by Chagas’ disease, with other ...
Claudio R. Gimpelewicz, Efraín A. Gómez, Felipe Martinez, Felix Ramires, Jean L. Rouleau, John J.V. McMurray, Karl Swedberg, Kenneth Dickstein, Lars Køber, Li Shen, Luis Eduardo Echeverría, Luiz Carlos Bodanese, Michael R. Zile, Milton Packer, null null, Pardeep S. Jhund, Scott D. Solomon, William T. Abraham   +17 more
core   +3 more sources

A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction [PDF]

, 2020
Aims The PARADIGM-HF and PARAGON-HF trials tested sacubitril/valsartan against active controls given renin–angiotensin system inhibitors (RASi) are ethically mandated in heart failure (HF) with reduced ejection fraction and are used in the vast majority ...
Claggett, Brian L, Jhund, Pardeep S., Lefkowitz, Martin, McMurray, John J.V., Packer, Milton, Rizkala, Adel, Seferovic, Petar, Shi, Victor, Solomon, Scott D, Vaduganathan, Muthiah, Widimský, Jiri   +10 more
core   +1 more source

Sacubitril/Valsartan Ameliorates Inflammation and Oxidative Stress in Hypertensive Heart Disease by Upregulating CAMKK2 Protein and Modulating the AMPK/AKT/GSK‐3β Axis

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Sacubitril/valsartan (Sac/Val) has emerged as an effective compound with myocardium‐protective functions in experimental and clinical trials for heart failure. This study investigated the function of Sac/Val in hypertensive heart disease (HHD) and explored the underlying mechanism.
Yan‐Jun Yang, Jiu‐Sheng Li
wiley   +1 more source

Has the 'epidemic’ of heart failure been replaced by a tsunami of co-morbidities? [PDF]

, 2016
No abstract ...
Bhatt, Callender, Cohen-Solal, Cowie, Ezekowitz, Fitchett, Jhund, Jhund, Komajda, Kotecha, Parén, Redfield, Schmidt, Scirica, Tavazzi, Urso, Vardas, Wasywich   +17 more
core   +1 more source

Circadian Immunity and Vascular Inflammation in Cardiovascular Disease Chronotherapy Windows: Time for a Re‐Assessment

Med Research, EarlyView.
ABSTRACT Circadian rhythms orchestrate cardiovascular physiology by regulating immune and inflammatory pathways. Disruption of these rhythms profoundly alters vascular homeostasis, thereby promoting the onset and progression of cardiovascular diseases (CVD).
Tian Zhang, Ge Zhang, Tian‐Ding Liu, Tianshu Gu, Fengyi Yu, Pengyuan Xu, Wunan Mi, Xuanjiang Zhao, Qian Guo, Honglin Zheng, Taiqi Zhao, Qiang Li, Di Lu, Mingxuan Duan, Chaoyang Yu, Ruhao Wu, Shiqian Zhang, Haonan Zhang, Zeyu Wang, Youyang Zheng, Yan Xiao, Zenglei Zhang, Ge Zhang   +22 more
wiley   +1 more source

Efficacy and safety of sacubitril/valsartan in the treatment of middle-aged and elderly patients with hypertension: a systematic review and meta-analysis of randomized controlled trials [PDF]

, 2022
Hong-Xing Wu, Keke Liu, Bo‐Ning Li, Sha Liu, Jingchun Jin   +4 more
openalex   +1 more source

Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. [PDF]

, 2018
AIMS: We tested the hypothesis that candesartan improves outcomes in heart failure (HF) with mid-range ejection fraction [HFmrEF; ejection fraction (EF) 40-49%].
Borlaug, Chioncel, Echocardiographic Normal Ranges Meta-Analysis of the Left Heart Collaboration, Fonarow, Koh, Lam, Lam, Lang, Lofman, Lupon, Mele, Meta-analysis Global Group in Chronic Heart Failure (MAGGIC), Nauta, Paulus, Pfeffer, Ponikowski, Rastogi, Rickenbacher, Sartipy, Solomon, Solomon, Solomon, Swedberg, Tsuji, Vedin, Yusuf   +25 more
core   +2 more sources

Renal function dynamics following co-administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes [PDF]

, 2020
The aim of this study was to evaluate the safety profile in terms of changes in renal function after co-treatment with sacubitril/valsartan and empagliflozin in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF).
Bayés-Genís, Antoni, Bravo, Rafael, De la Espriella, Rafael, Fácila, Lorenzo, Górriz, Jose Luis, Miñana, Gema, Morillas, Herminio, Núñez, Eduardo, Núñez, Julio, Sanchis, Juan, Santas, Enrique, Torres, Francisco, Valle, Alfonso, Vidal, Verónica   +13 more
core   +1 more source